5 Years Later: My Pandemic Predictions on Learning Loss, Disengagement and More
It turns out that educational disruptions are bad for kids.
Perhaps you already knew that?
In a series of posts in 2020 and 2021, I wrote about the research on past educational disruptions and predicted what they might mean for children going through COVID-19.
Get stories like this delivered straight to your inbox. Sign up for The 74 Newsletter
Get stories like this delivered straight to your inbox. Sign up for The 74 Newsletter
This month marks the fifth anniversary of the pandemic. What have we learned since then? Here's my analysis of what I got right and what I got wrong:
Prediction No. 1: Lost learning time will translate into lost learning.
As I wrote in 2021, 'Years and sometimes even decades after a disruption in schooling, researchers are able to detect noticeable differences in student outcomes.'
COVID's effects were so large that they showed up immediately. And they were worse for students who missed more school. For example, a recent international analysis in Nature concluded that, 'countries with the shortest closures experienced relatively small losses' and 'countries with the longest closures, experienced losses of … 9 to 12 months of learning.' Here in the States, a team of researchers led by University of Washington economist Dan Goldhaber found that remote instruction was the 'primary driver of widening achievement gaps.'
Predictions No. 2 and 3: The losses are likely to be large. Their full extent may not show up immediately, but small losses can grow over time.
In 2020 and 2021, I was looking at localized events like an earthquake in Pakistan or teacher strikes in Argentina. Researchers found noticeable negative effects from these events, but there was no modern precedent for the scale and length of the COVID-related disruptions.
Related
Here in the States, the average student fell behind by the equivalent of half a grade level in math and one-third of a grade level in reading. Today, with federal COVID funding ending, student performance is still far below where it was.
Prediction No. 4: Learning losses are likely to be larger in younger children.
Based on prior research, I anticipated that kids in middle school and high school might transition to remote learning better than their younger siblings. But it's hard to know which age group ultimately struggled the most. ACT scores for high schoolers fell to 30-year lows, but so did fourth and eighth grade math and reading scores. Curriculum Associates data point to ongoing gaps among younger kids, while NWEA data suggest middle schoolers are the furthest behind. In other words, there's no biggest loser here; achievement is down across the board.
Prediction No. 5: Math scores are likely to drop the most.
Math skills are generally picked up at school, while in English Language Arts, proficiency is more closely linked to a student's home environment. That shows up in the data: Math scores declined more when students were learning remotely and have shown more signs of recovery since then.
Meanwhile, reading scores have continued to decline. That could partly reflect broader societal trends, but state leaders should be looking toward Mississippi and other Southern states for ideas on how to get those back on track.
Prediction No. 6: Beyond academic losses, students are at risk of disconnecting from education.
In 1916, schools in many parts of the country closed for weeks in the midst of a polio outbreak. Researchers later found that those shutdowns caused some students to drop out of school and never return.
More than a century later, COVID magnified this to an extreme, changing the relationship kids had with school and leading to huge spikes in chronic absenteeism. While those rates have come down a bit from their highs in 2022, I didn't anticipate just how much COVID would break cultural norms around school attendance, and how hard it would be for schools to restore those (good) habits.
Prediction No, 7: Higher-income students may not suffer any noticeable effects.
I underappreciated how much a district's decisions about in-person versus remote schooling would have on all students. The Goldhaber paper found that, 'even at low-poverty (high income) schools, students fell behind growth expectations when their schools went remote or hybrid.'
Related
Still, higher-income and higher-performing students have managed the post-pandemic recovery better than others. For example, in eighth-grade math, the top 10% of students made noticeable gains from 2022 to 2024, while scores continued to fall for lower-performing students. At the high school level, the percentage of students who took and passed an Advanced Placement test dipped in the wake of COVID but has now surpassed pre-pandemic levels. Similarly, the percentage of high school students who are also taking credit-bearing college courses is hitting all-time highs. In other words, even as average achievement scores are down, many more high school students are finding ways to take more advanced courses.
However, this leads to …
Prediction No. 8: Low-income and disadvantaged students will suffer the biggest losses.
The virus may have been the same, but it did not affect everyone equally. As I noted last year, all kids missed more school in the wake of the pandemic, but those increases varied substantially. For example, the kids with the best attendance records missed about one extra day of school per year, while the kids with the worst absentee rates missed multiple weeks worth of school time.
The same trends appear in achievement scores: The bottom has fallen out across a variety of tests, grades and subjects.
Prediction No 9: The COVID-induced recession will affect children, families and schools in many ways.
The pandemic's effects on students have the potential to be long-lasting. For example, the study of teacher strikes in Argentina found that the children of strike-affected students were more likely than their peers to be held back in school. That is, the effects passed on to later generations.
But beyond the students themselves, no one could have anticipated all the downstream effects of the COVID school closures. They are at least part of the story behind public school enrollment declines, families moving away from blue states and urban areas, and declining satisfaction with the nation's public schools, not to mention broader political realignments.
Prediction No. 10: Without any action, the losses are likely to have long-term consequences.
To its credit, Congress provided states and school districts with $190 billion in 2020 and 2021. As hard as it is to fathom, the best research suggests it would take a lot more money to get kids fully back on track. The achievement declines were that large.
The money is now gone, and the national conversation has moved on. But I'm struck by what I wrote a few years ago: that if policymakers don't act to get kids back on track, they will be, 'condemning a generation of children to worse academic and economic outcomes throughout their life.'
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
27 minutes ago
- Yahoo
People with Covid-like symptoms took almost a year before feeling like themselves again, researchers say
Did you have Covid-like symptoms? It may take nine months or even longer to start feeling like yourself again. Researchers at UCLA found that 20 percent of patients with those symptoms continued experiencing suboptimal quality of life for nearly a year after infection. Whereas, physical well-being returned after only three months. "We have newly recognized the difference in recovery with respect to mental vs. physical well-being after a COVID infection," Lauren Wisk, an assistant professor of medicine at UCLA, said in a statement. "The findings showed that health care professionals need to pay more attention to their patients' mental well-being after a Covid infection and provide more resources that will help improve their mental health, in addition to their physical health,' she added. Wisk was one of the lead authors of the Centers for Disease Control and Prevention-funded study that was published Tuesday in the journal Open Forum Infectious Diseases. The study compared people who sought treatment for Covid-like symptoms. Of those, 75 percent tested positive for the virus. The rest were negative. Of the 4,700 participants who experienced the symptoms between mid-December 2020 and late August 2022, the people who were positive for Covid were statistically likelier to return to optimal health-related quality-of-life than their Covid-negative counterparts in the year following the infection. The authors said the findings suggest that health authorities may have previously underestimated the long-term effects of non-Covid infections on a patient's well-being. To reach these conclusions, researchers analyzed responses from nearly 1,100 Covid-positive patients and 317 Covid-negative negative patients, assessing aspects including physical function, anxiety, depression, fatigue, social participation, sleep disturbance, pain interference and cognitive function. They found that approximately one in five of those who were part of the study remained in poor overall quality of life, with a high likelihood of self-reporting long Covid for up to a year after initial infection. 'In this large, geographically diverse study of individuals with 12 months of follow-up after Covid-19-like illness, a substantial proportion of participants continued to report poor [overall quality of life], whether or not the inciting acute symptoms were due to SARS-CoV-2 or another illness,' they said. Mental well-being recovered gradually, with significant improvements manifesting between six and nine months after infection, researchers found. The authors said further research was needed, noting that it remains unclear which conditions the symptomatic Covid-negative patients were suffering from and that Covid tests can yield both false-positive and false-negative results. The common cold, allergies, flu and Covid share many similar symptoms. "Future research should focus on how to improve the treatment models of care for patients who continue to experience Covid-19 symptoms and their impact on patients' quality of life, especially as one in five patients may continue to suffer over a year after their initial infection, which likely reflects long Covid," Wisk said.
Yahoo
an hour ago
- Yahoo
PointClickCare Pledges $75,000 to the Senior Living CaRES Fund in Support of Education Grants for Senior Living Workers
Leading health tech company commemorates National Long-Term Care Day with three-year commitment aimed at strengthening and empowering Canada's senior living workforce TORONTO, June 13, 2025 /CNW/ -- PointClickCare, a leading health tech company helping providers deliver exceptional care, today announced a three-year philanthropic partnership with the Senior Living CaRES Fund. The company will contribute $25,000 annually — totaling $75,000 — to fund educational grants that support professional development for workers in long-term care and retirement communities across Canada. Founded in 2020, the Senior Living CaRES Fund has provided over $3 million in emergency financial assistance and educational grants to frontline workers. The fund recognizes the vital role senior living professionals play in caring for older adults and is committed to fostering a stronger, more resilient workforce. "At PointClickCare, we believe that investing in people is the most meaningful way to drive lasting impact," said Angeline Pleunis, Vice President, Workplace Experience & Social Impact at PointClickCare. "The individuals working in senior living communities play an essential role in the health and well-being of our aging population, and they deserve every opportunity to grow, thrive, and succeed in their careers. Our partnership with the Senior Living CaRES Fund reflects our deep commitment to supporting this incredible workforce through education and development." The COVID-19 pandemic highlighted significant challenges in long-term care and heavily burdened frontline staff. These workers showed, and continue to show, remarkable resilience and compassion, often making personal sacrifices. It's clear that investing in their education and development is essential. PointClickCare's support enhances access to continuing education and training, equipping staff to excel in their careers and improve care quality. "We are incredibly grateful for PointClickCare's generous commitment to the Senior Living CaRES Fund," said Rebecca Scott Rawn, Executive Director at Senior Living CaRES Fund. "Their support will directly empower frontline workers with access to education and professional development opportunities – tools that not only enhance individual careers but strengthen the quality of care for seniors across Canada. Together, we are investing in the champions who make compassionate care possible every day." On National Long-Term Care Day, PointClickCare and the Senior Living CaRES Fund are proud to honour the dedication of those working in senior living communities. Together, they are investing in a future where every senior living worker feels valued, supported, and empowered to make a lasting impact. To learn more about PointClickCare's award-winning culture and philanthropic programs, visit the website here. For more information on the Senior Living CaRES Fund, visit the website here. About PointClickCarePointClickCare is a leading health tech company with one simple mission: to help providers deliver exceptional care. With the largest long–term and post–acute care dataset, we power AI-driven healthcare to deliver intelligent transitions, insightful interventions, and improved financial performance. Enhanced by our marketplace of 400+ integrated partners and trusted by over 30,000 provider organizations and every major U.S. health plan, we're redefining healthcare, so it doesn't just survive — it thrives. About The Senior Living CaRES FundEstablished in May 2020 by founding partners Chartwell Retirement Residences, Revera Inc., Extendicare, and Sienna Senior Living, the Senior Living CaRES Fund was created in recognition of the extraordinary efforts of senior living sector employees whose passion, commitment and resilience while caring for the most vulnerable is nothing short of heroic. Since its establishment, the Fund has assisted over 970 employees across the country, distributing more than $3.1 million in emergency financial aid and bursaries for education. Media ContactPointClickCareMedia@ SOURCE PointClickCare View original content to download multimedia: Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
an hour ago
- Yahoo
Moderna's mRNA RSV vaccine wins expanded FDA approval for younger adults
The US Food and Drug Administration (FDA) has expanded approval of Moderna's respiratory syncytial virus (RSV) vaccine to include younger adults at risk, though its still uncertain whether the shot will be recommended for broader use in the national immunisation schedule. Moderna's vaccine, known under the brand name mRESVIA, became the first non-Covid-19 messenger RNA-based (mRNA) vaccine to be approved in the US in May 2024. Until now, the vaccine was licensed for the prevention of lower respiratory tract disease (LRTD) caused by RSV in adults aged 60 years and older. The expanded approval now includes individuals aged 18 to 59 who are at risk of RSV. This approval was supported by results from Moderna's Phase III study (NCT06067230), which demonstrated the vaccine's immune response worked just as well in this age group compared to the existing approved age group of 60 years and older. Infants and older adults remain the most vulnerable age groups to RSV, though over one-third of adults between 18 and 59 years of age have at least one underlying condition that puts them at increased risk of developing a severe form of the disease. "RSV poses a serious health risk to adults with certain chronic conditions, and today's approval marks an important step forward in our ability to protect additional populations from severe illness from RSV," said Stéphane Bancel, Chief Executive Officer of Moderna. Moderna said it plans to have mRESVIA available for both both younger adults and older adults in the US in time for the 2025-2026 respiratory virus season. This usually begins around November and peaks in the mid-Winter months. mRESVIA is the second approved product in the US for Moderna, along with its Covid-19 vaccine Spikevax. The pharma company has been seeking outside investment to fund late-stage trials for further infectious disease vaccine candidates, amid a strategy to diversify its portfolio. Whilst the label expansion reflects an easing in regulatory tension surrounding mRNA vaccines under the Trump administration, FDA approval does not automatically mean shots enter national immunisation schedules. That is instead decided by the US Centers for Disease Control and Prevention's (CDC) Advisory Committee on Immunization Practices (ACIP). The CDC currently recommends the vaccine for adults aged 75 and older, as well as for adults aged 60 to 74 who are at increased risk of infection. In April, the CDC's ACIP recommended the use of approved RSV vaccines in at-risk adults aged 50 to 59. This week, US health secretary Robert F Kennedy (RFK) Jr axed the entire ACIP panel of experts, replacing members with vaccine sceptics and individuals with no prior public health strategy experience. The reshuffle has raised concerns about the future of the US immunisation schedule and the scope of vaccine recommendations. 'Investor focus will likely shift to the CDC's ACIP's next meeting, which is scheduled to proceed on June 25-27,' said William Blair analyst Miles Minter in a research note. 'This will be the first time for investors to see the refreshed ACIP in action and will be important for sentiment in the vaccine sector, which continues to decline in our view. Ultimately, we see the biggest headwind to the RSV vaccination market as restrictive ACIP recommendations that do not include re-dosing potential,' Minter added. The label expansion sees Moderna catch up with Pfizer, which already has an RSV vaccine approved for adults aged 18 years and over. Like mRESVIA, Pfizer's Abrysvo has the requirement of increased disease risk for those between 18 and 59, whilst anyone above the age of 60 is eligible for the jab. Pfizer still has a market advantage, however, with Abrysvo the only vaccine product approved for infants. It also gained FDA approval a year before mRESVIA, giving it first to market advantage. GSK also has an FDA-approved vaccine in the form of Arexvy, though its label only covers those at risk in individuals aged between 50 through 59 years, along with the standard indication of ages 60 and over. "Moderna's mRNA RSV vaccine wins expanded FDA approval for younger adults" was originally created and published by Pharmaceutical Technology, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data